Meeting NewsVideo

VIDEO: Neratinib, capecitabine demonstrate ‘impressive’ results in metastatic breast cancer

TBCRC 022, a phase 2 trial of neratinib plus capecitabine in patients with HER-2-positive breast cancer and brain metastases, was a “fascinating study,” according to Jane Meisel, MD, medical oncologist at the Winship Cancer Institute and assistant professor in the department of hematology and medical oncology at Emory University School of Medicine.

More than 50% of patients (23 out of 39) were alive at 12 months, according to findings presented at the ASCO Annual Meeting.

“One of the things that’s been interesting, and somewhat frustrating … is that systemic therapy is getting so good, but so little of it crosses the blood-brain barrier…” Meisel said. ”This is a combination that definitely warrants further study and may be able to make its way into the clinic as a significant remedy to that problem.”

TBCRC 022, a phase 2 trial of neratinib plus capecitabine in patients with HER-2-positive breast cancer and brain metastases, was a “fascinating study,” according to Jane Meisel, MD, medical oncologist at the Winship Cancer Institute and assistant professor in the department of hematology and medical oncology at Emory University School of Medicine.

More than 50% of patients (23 out of 39) were alive at 12 months, according to findings presented at the ASCO Annual Meeting.

“One of the things that’s been interesting, and somewhat frustrating … is that systemic therapy is getting so good, but so little of it crosses the blood-brain barrier…” Meisel said. ”This is a combination that definitely warrants further study and may be able to make its way into the clinic as a significant remedy to that problem.”

    See more from Discoveries from ASCO: Breast Cancer